Accuray reported revenue gains for the second quarter of fiscal year 2022 and cited orders for technology upgrades on its Radixact platform as a driver.
The company reported net revenues of $116.4 million for the second quarter (end-December 31, 2021), an increase of 19% compared with the second quarter of the last fiscal year. Accuray said gross orders reached $85.4 million, an increase of 13% compared with the prior year. The company said its net income under generally accepted accounting principles (GAAP) was $200,000 for the quarter, compared with $4.8 million in the second quarter of last year.
Company executives cited continued strong demand for its ClearRT helical fanbeam kVCT imaging system since its commercial release in December 2020, as well as recent Shonin approval in Japan for use of its CyberKnife robotic radiotherapy platform for the treatment of trigeminal neuralgia.
